SCHEMBL2043746

SCHEMBL2043746

COc1cc(Cl)cc(NCc2ccccc2O)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.50
HSD17B10 Q99714 1/20 0.50
HPGD P15428 4/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 7/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 2/20 0.46
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
PKM P14618 1/20 0.43
EGFR P00533 1/20 0.42
NOX4 Q9NPH5 1/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2040207 0.84 SMN1; SMN2 (0.52) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2043902 0.84 NPSR1 (0.45) NPSR1HPGDMAPTMEN1KMT2A
SCHEMBL2040677 0.81 NPSR1 (0.67) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2045770 0.80 MAPT (0.55) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2039801 0.79 NOX4 (0.48) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2049067 0.78 HSD17B10 (0.52) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2046213 0.77 NPSR1 (0.57) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2045682 0.76 MAPT (0.54) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL2049069 0.76 NPSR1 (0.50) NPSR1HSD17B10HPGDALDH1A1MAPT
SCHEMBL19971036 0.76 KMT2A (0.53) NPSR1HSD17B10HPGDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516398-B1 PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE GALDERMA RES & DEV (FR) 2018-03-21 EP claimed
US-9505720-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-11-29 US claimed
US-20160115132-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-04-28 US claimed
US-9050266-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-06-09 US claimed
US-20140275536-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-09-18 US claimed
EP-2516398-A2 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP claimed
WO-2011077043-A2 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO claimed
EP-2516398-B1 PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE GALDERMA RES & DEV (FR) 2018-03-21 EP disclosed
US-20170037015-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-02-09 US disclosed
US-9505720-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-11-29 US disclosed
US-20160115132-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-04-28 US disclosed
US-9050266-B2 Phenol derivatives and pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-06-09 US disclosed
US-20140275536-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-09-18 US disclosed
EP-2516398-A2 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077043-A2 PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037015-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, TEAD3 NPSR1 1708/4885HSD17B10 145/4885HPGD 103/4885
US-20140275536-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA NPSR1 2580/4885HSD17B10 204/4885HPGD 84/4885
US-20160115132-A1 NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, TEAD3 NPSR1 1708/4885HSD17B10 145/4885HPGD 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.